By Joel Lord
As far back as 2006 no fewer than 4 major pharmaceutical companies had applied for vaccine patents to combat a novel strain of H1N1 virus: GlaxoSmythKline, Novartis, Baxter International & Medimmune:
GlaxoSmithKline Patent WO2006100109 A1 / March 21st, 2006
Novartis Patent US 20090047353 / November 6th, 2006
Baxter Patent US 20090060950 A1 / 2008
Medimmune Patent US 20081006921 A1 / 2008
Fast forward to August 6th, 2009. The World Health Organization released this statement from Geneva,
‘Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines. Different regulatory pathways were assessed, and precautions needed to ensure quality, safety, and effectiveness were set out in detail.
Some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus. Such advance studies can greatly expedite regulatory approval.’
Even more sinister on June 1st, 2005 a team of microbiologists from Mount Sinai Hospital applied for a novel H1N1 Influenza Virus Patent. Why was it only approved on January 8th, 2009, just 3 months before the sudden outbreak in Mexico? …and exactly who funded them?